Atezolizumab in combination with Bevacizumab inhibited the proliferation, migration, and invasion of cisplatin resistant ovarian cancer cell in vitro synergistically via Bevacizumab suppressing EMT and PD-L1 expression by targeting STAT3. The gene discussed is CD274; the disease is ovarian cancer.